A series of dice with a bag on them illustrating cost cuts
Biotech

Cellectis will shed 70% of workforce as part of in vivo pivot

Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
James Waldron Nov 13, 2026 9:18am
Stock market IPO share price

Sanofi-backed Windward hits $225M IPO, as Rezera delays listing

Nov 13, 2026 7:10am
Regeneron

Regeneron posts positive ph. 2 POTS data, eyes pivotal trial

Nov 13, 2026 3:31am
Charles River booth at AACR 2026

Charles River pays $470M for 2 Frontage labs in Pennsylvania

Nov 13, 2026 11:00am
Podcast
The Top Line podcast logo

The promise of molecular gates and what comes next

Nov 13, 2026 9:58am
blocks stack target climb build arrow meet

Rezolute gets an uplift from ph. 3 win ahead of FDA meet

Nov 13, 2026 9:30am
More News

Researchers identify protein panel to improve ALS detection

Nov 13, 2026 9:00am

BMS unites R&D as chief of research departs—Chutes & Ladders

Nov 13, 2026 8:30am

Fierce Biotech Layoff Tracker 2026: Milestone, Cellectis & more

Nov 13, 2026 7:00am

ARPA-H bets $4.9 million on ibogaine to treat PTSD in veterans

Nov 12, 2026 2:56pm